Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zevra Therapeutics

7.87
+0.08001.03%
Post-market: 7.870.00000.00%16:05 EDT
Volume:363.46K
Turnover:2.90M
Market Cap:430.33M
PE:-3.45
High:8.08
Open:7.82
Low:7.82
Close:7.79
Loading ...

Zevra Therapeutics Inc - Zevra Has Discontinued Its in-House Drug Discovery Activities

THOMSON REUTERS
·
07 Dec 2024

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has caught the attention of institutional investors who hold a sizeable 42% stake

Simply Wall St.
·
07 Dec 2024

Zevra Therapeutics Launches MIPLYFFA for Niemann-Pick Disease

TIPRANKS
·
22 Nov 2024

Zevra Therapeutics Gains Buy Rating Amid Successful MIPLYFFA Launch and Strong Market Response

TIPRANKS
·
22 Nov 2024

Zevra Niemann-Pick disease type C drug Miplyffa now available

seekingalpha
·
22 Nov 2024

BRIEF-Zevra Therapeutics Announces U.S. Commercial Availability Of Miplyffa For Treatment Of Niemann-Pick Disease Type C

Reuters
·
22 Nov 2024

Zevra Therapeutics Announces U.S. Commercial Availability of Miplyffa™ (Arimoclomol) for Treatment of Niemann-Pick Disease Type C

THOMSON REUTERS
·
22 Nov 2024

Zevra Therapeutics Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Dow Jones
·
20 Nov 2024

Zevra Therapeutics: Strong Financials, Strategic FDA Approval, and Growth Prospects Drive Buy Rating

TIPRANKS
·
15 Nov 2024

Zevra Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
15 Nov 2024

Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
14 Nov 2024

Zevra Therapeutics price target lowered to $23 from $25 at Canaccord

TIPRANKS
·
14 Nov 2024

Zevra Therapeutics (ZVRA) Receives a Buy from Roth MKM

TIPRANKS
·
13 Nov 2024

Strategic Advancements and Promising Outlook Drive Zevra Therapeutics’ Growth Prospects

TIPRANKS
·
13 Nov 2024

Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

GuruFocus.com
·
13 Nov 2024

Zevra Therapeutics: Strong MIPLYFFA Launch and Strategic Investments Justify Buy Rating Despite OLPRUVA Challenges

TIPRANKS
·
13 Nov 2024

Zevra Therapeutics’ Transformative Third Quarter 2024

TIPRANKS
·
13 Nov 2024

Zevra Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
13 Nov 2024

Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates

Zacks
·
13 Nov 2024

Zevra Therapeutics: Q3 Earnings Snapshot

Associated Press Finance
·
13 Nov 2024